China SXT Pharmaceuticals Inc logo

China SXT Pharmaceuticals Inc(SXTC)

upturn advisory logo
ADVISORIES YOU CAN VERIFY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$2.4
09/18/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close

Advisory Performance History (Simulated)Advisory Performance History info

Upturn Advisory & Investor View for SXTC

09/18/2026: SXTC (1-star) is currently NOT-A-BUY. Pass it for now.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -61.63%
Avg. Invested days 8
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 09/18/2026

Upturn Scorecard

Upturn Star Rating

SXTC receives a 2-star rating, supported by available scored pillars. The rating is constrained by weak unit economics, soft company fundamentals, and soft quantitative characteristics.

Company Fundamentals

SXTC has soft overall fundamentals (2 stars), with soft financial health, weak growth momentum, and moderate ownership. In FY2026 versus FY2025, growth and ownership metrics are mixed: negative earnings growth (-87.8%), soft cash generation (FCF margin -374.5%), negative revenue growth (-38.4%).

Financial Health Rating

SXTC's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 86.8%). Operating efficiency is weak (1 stars), which helps explain the 2-star overall score.

Growth Momentum Score

SXTC's growth profile is soft, with the least-weak measure being revenue growth at -38.4% FY2026 versus FY2025. By comparison, while earnings growth (-87.8%, negative) and free-cash-flow growth (-71.1%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

Institutional ownership is 0.0% and approximately 30.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 33.37% supports management-shareholder alignment.

Top 5 Institutional Investors

Sabby Management LLC 0.20%
Royal Bank of Canada 0.00%
Caitong International Asset Management Co., Limited. 0.00%
UBS Group AG 0.00%
Amvescap Plc. 0.00%

Unit Economics (Per $1K Revenue)

SXTC generates approximately $171 of gross profit, $-6,641 of operating income, and $-3,745 of free cash flow for every $1,000 of revenue. Based on FY2026 results. Strong cash conversion and healthy margins support the rating, although capital efficiency remains below the highest tier.

Economic Dimensions

Effective Tax Rate: -2.15% (Tax Credit)

Quantitative Style Profile

SXTC has a High Volatility Profile profile. Weak momentum is the primary drawback, while elevated volatility.

Style Classification

Quality Focused

Value-OrientedHigh VolatilitySmall / Mid Cap Risk

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.17M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) 3.5M shares
Beta 1.84
52 Weeks Range 0.04 - 307.59
Updated Date 09/20/2026
52 Weeks Range 0.04 - 307.59
Updated Date 09/20/2026
Dividends yield (FY) -
Basic EPS (TTM) -730.4

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Advertisement

Valuation

Trailing PE -
Forward PE -
Enterprise Value -23.88M
Price to Sales(TTM) 2.79
Enterprise Value -23.88M
Price to Sales(TTM) 2.79
Enterprise Value to Revenue 43.06
Enterprise Value to EBITDA 7.08
Shares Outstanding 1.32M
Shares Floating 401.68K
Shares Outstanding 1.32M
Shares Floating 401.68K
Percent Insiders 33.37
Percent Institutions -

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

About China SXT Pharmaceuticals Inc

Exchange NASDAQ
Headquarters -
IPO Launch date 2019-01-04
Chairman of the Board & Co-CEO Mr. Feng Zhou
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Full time employees 56
Full time employees 56

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.